News Story: Full Text
Sponsored By
NovoCure Trial
Please Click On The Above Banner For More Details
Braintumor Website


SNO 2018: Trials of Two Oncolytic Viruses for Recurrent Malignant Glioma Are Progressing


Al Musella's Comments: (This is his personal views and are not necessarily the views of the Musella Foundation!)

 2 interesting treatments. Too early to tell how well they are working, as both are just trying to find the right dosage. They both have some long term survivors. Historically, the survival after recurrence for a GBM is about  7 months.  The Polio Virus Vaccine has about 20% of patients alive ranging from 36-73 months. The D2C7-IT trial has about 30% of patients alive, with 2 of them having partial responses and being alive over 8.2 and 34 months.  

 

Disclaimer:  The Musella Foundation has funded both treatments.


Posted on: 11/22/2018

SNO 2018: Trials of Two Oncolytic Viruses for Recurrent Malignant Glioma Are Progressing

 




Click HERE to return to brain tumor news headlines


Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2018 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557
888-295-4740